![Shelia Violette](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Shelia Violette
Plus aucun poste en cours
Fortune : 3 M $ au 31/07/2026
Profil
Shelia Violette is the founder of Q32 Bio, Inc., founded in 2017, serving as Chief Scientific Officer & President-Research since 2024.
Current jobs include Advisor at Atlas Venture Advisors, Inc. since 2021 and Chief Scientific Officer at Q32 Bio Operations, Inc. since 2017.
Former jobs include Director at CytImmune Sciences, Inc. from 2021 to 2023, Principal at Repligen Corp., Principal at ARIAD Pharmaceuticals, Inc., Vice President-Research at Biogen, Inc., and Vice President-Research at Stromedix, Inc. Education includes a doctorate from Yale University conferred in 1989.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,55 % | 25/08/2026 | 164 048 ( 0,55 % ) | 3 M $ | 31/07/2026 |
Postes actifs de Shelia Violette
| Sociétés | Poste | Début |
|---|---|---|
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Develops immunomodulatory therapies with protein based molecules using a platform | Directeur Technique/Scientifique/R&D | 01/01/2017 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for early stage capital requirements. | Consultant / Advisor | 01/01/2021 |
Anciens postes connus de Shelia Violette
| Sociétés | Poste | Fin |
|---|---|---|
CytImmune Sciences, Inc.
 CytImmune Sciences, Inc. BiotechnologyHealth Technology Develops and manufactures cytokine immunoassay kits | Directeur/Membre du Conseil | 01/06/2023 |
| BIOGEN INC. | Directeur Technique/Scientifique/R&D | - |
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| REPLIGEN CORPORATION | Corporate Officer/Principal | - |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Directeur Technique/Scientifique/R&D | - |
Formation de Shelia Violette
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
95
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Repligen Corp.
 Repligen Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures biologic drugs | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
CytImmune Sciences, Inc.
CytImmune Sciences, Inc. BiotechnologyHealth Technology Develops and manufactures cytokine immunoassay kits | Health Technology |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for early stage capital requirements. | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Develops immunomodulatory therapies with protein based molecules using a platform | Health Technology |
